Table 1. The roles of circRNAs in thoracic diseases and their possible mechanisms.
| CircRNAs | Diseases | Features and potential function | Ref. |
|---|---|---|---|
| hsa_circ_0067934 | ESCC | Correlate with tumor stage and inhibit cell proliferation | (34) |
| Cir-ITCH | ESCC; lung cancer | Sponge miR-7, miR-17, and miR-214 to increase ITCH expression, then degrade Dvl2 phosphorylation to further inhibit the Wnt signaling pathway | (35,36) |
| CircRNA_001059, CircRNA_000167 | Esophageal cancer | RT resistance | (37) |
| CDR1as | Lung cancer | Sponge miR-7 to inhibit apoptosis of cancer cells | (38) |
| MI | Sponge miR-7a to regulate PARP and SP1 | (39) | |
| Circ-ZEB1 | Lung cancer | Sponge miR-200 to regulate ZEB1 expression | (40) |
| Circ_100876 | NSCLC | Correlate with tumor stage and survival time | (41) |
| CircSLC8A1-1 | Heart disease | Most abundant heart-specific circRNAs | (42) |
| RBM20-dependent TTN circRNAs | DCM | Correlate with pathogenesis of DCM | (43) |
| HRCR | HCM | Sponge miR-233 to regulate ARC | (44) |
| CircRNA_081881 | AMI | Sponge miR-548 to regulate PPARγ | (45) |
| MICRA | MI | Predict LV function | (46) |
| hsa_circ_0124644 | CAD | Diagnostic biomarker | (47) |
| CircRNA_000203 | MF | Sponge miR-26b-5p to regulate Colla2 and CTGF | (48) |
ESCC, esophageal squamous cell carcinoma; RT, radiation therapy; MI, myocardial infarction; LV, left ventricular; NSCLC, non-small cell lung cancer; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; AMI, acute myocardial infarction; CAD, coronary artery disease; MF, myocardial fibrosis; TTN, titin; ARC, apoptosis repressor with CARD domain.